Successful Treatment of Full-Thickness Macular Hole in Polypoidal Choroidal Vasculopathy With Anti-VEGF Therapy

Aaron Lindeke-Myers, Gregg T. Kokame, Steven Yeh, Jessica Shantha

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Purpose: This report discusses the case of an 86-year-old man with a full-thickness macular hole (FTMH) secondary to polypoidal choroidal vasculopathy (PCV) treated with bevacizumab. Methods: A case report is presented. Results: An 86-year-old man presented with a 5-month history of metamorphopsia and decreased vision in his right eye and was found to have active exudation secondary to PCV with a concurrent FTMH. After 4 treatments with intravitreal bevacizumab, the FTMH resolved without surgical intervention. Conclusions: The patient’s FTMH resolved with solely pharmacologic treatment as a result of treating his PCV with intravitreal bevacizumab. Macular hole formation secondary to PCV is a rare finding, but may be successfully treated with pharmacologic therapy without surgical intervention.

Original languageEnglish (US)
Pages (from-to)433-436
Number of pages4
JournalJournal of VitreoRetinal Diseases
Volume4
Issue number5
DOIs
StatePublished - Sep 1 2020
Externally publishedYes

Keywords

  • bevacizumab
  • full-thickness macular hole
  • macular hole
  • polypoidal choroidal vasculopathy

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Successful Treatment of Full-Thickness Macular Hole in Polypoidal Choroidal Vasculopathy With Anti-VEGF Therapy'. Together they form a unique fingerprint.

Cite this